TransCode Therapeutics (NASDAQ:RNAZ) Stock Price Down 12.1% – Time to Sell?

TransCode Therapeutics Inc. (NASDAQ:RNAZ)’s share price was down 12.1% on Thursday . The company traded as low as $4.70 and last traded at $4.70. Approximately 31,649 shares were traded during mid-day trading, a decline of 78% from the average session volume of 145,095 shares. The stock had previously closed at $5.35.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of TransCode Therapeutics in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

TransCode Therapeutics Stock Performance

The company has a 50 day moving average of $6.87 and a 200 day moving average of $8.24. The stock has a market capitalization of $4.46 million, a price-to-earnings ratio of -0.09 and a beta of 1.28.

TransCode Therapeutics (NASDAQ:RNAZ) last announced its earnings results on Friday, May 15th. The company reported ($21.28) earnings per share (EPS) for the quarter.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.